Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/22/2026

1. USO
2. DHR
3. SPY
4. NVDA
5. NOW
6. AMD
7. GM
8. SMCI
9. IBM
10. EFX

Go back to Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
(NASDAQ: KYMR) Delayed: 110.34 -3.03 (2.67%)
Previous Close $113.37    52 Week High $ 
Open $110.92    52 Week Low $ 
Day High $113.63    P/E N/A 
Day Low $110.18    EPS $ 
Volume 538,338